Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | NR4A2 | P43354 | 1/20 | 0.49 |
| ▸ | L3MBTL1 | Q9Y468 | 1/20 | 0.46 |
| ▸ | ALDH1A1 | P00352 | 6/20 | 0.45 |
| ▸ | LMNA | P02545 | 1/20 | 0.45 |
| ▸ | GAA | P10253 | 3/20 | 0.44 |
| ▸ | SLC6A3 | Q01959 | 1/20 | 0.44 |
| ▸ | CA12 | O43570 | 1/20 | 0.43 |
| ▸ | CA1 | P00915 | 1/20 | 0.43 |
| ▸ | CA2 | P00918 | 1/20 | 0.43 |
| ▸ | CA7 | P43166 | 1/20 | 0.43 |
| ▸ | PDK2 | Q15119 | 1/20 | 0.43 |
| ▸ | PDK4 | Q16654 | 1/20 | 0.43 |
| ▸ | CA9 | Q16790 | 1/20 | 0.43 |
| ▸ | CA14 | Q9ULX7 | 1/20 | 0.43 |
| ▸ | ABCG2 | Q9UNQ0 | 2/20 | 0.42 |
| ▸ | KDM4E | B2RXH2 | 4/20 | 0.42 |
| ▸ | HSD17B10 | Q99714 | 2/20 | 0.42 |
| ▸ | MAPT | P10636 | 2/20 | 0.41 |
| ▸ | HPGD | P15428 | 2/20 | 0.41 |
| ▸ | GLA | P06280 | 1/20 | 0.41 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL30752924 | 1.00 | NR4A2 (0.49) | NR4A2L3MBTL1ALDH1A1LMNAGAA | |
| SCHEMBL3712715 | 0.88 | NR4A2 (0.50) | NR4A2L3MBTL1ALDH1A1LMNAGAA | |
| SCHEMBL30802482 | 0.87 | NR4A2 (0.47) | NR4A2L3MBTL1ALDH1A1LMNAGAA | |
| SCHEMBL12095473 | 0.87 | NR4A2 (0.47) | NR4A2L3MBTL1ALDH1A1LMNAGAA | |
| SCHEMBL29874714 | 0.86 | NR4A2 (0.49) | NR4A2L3MBTL1ALDH1A1LMNAGAA | |
| SCHEMBL16304136 | 0.86 | NR4A2 (0.49) | NR4A2L3MBTL1ALDH1A1LMNAGAA | |
| SCHEMBL391759 | 0.86 | NR4A2 (0.49) | NR4A2L3MBTL1ALDH1A1LMNAGAA | |
| SCHEMBL4468280 | 0.85 | NR4A2 (0.46) | NR4A2L3MBTL1ALDH1A1LMNAGAA | |
| SCHEMBL257356 | 0.85 | NR4A2 (0.48) | NR4A2L3MBTL1ALDH1A1LMNAGAA | |
| SCHEMBL27769962 | 0.85 | NR4A2 (0.48) | NR4A2L3MBTL1ALDH1A1LMNAGAA |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 1088 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| CN-111170991-B | Antiproliferative compounds and methods of synthesis thereof | 细胞基因公司 | 2023-10-31 | — | — | CN | claimed |
| CN-111170991-A | Antiproliferative compounds and methods of synthesis thereof | 细胞基因公司 | 2020-05-19 | — | — | CN | claimed |
| EP-4747244-A1 | MODULATORS OF RHO-ASSOCIATED PROTEIN KINASE | Redx Pharma Limited (GB) | 2026-05-27 | — | — | EP | disclosed |
| WO-2026106389-A1 | NMT INHIBITOR AND USE THEREOF | 주식회사 이노보테라퓨틱스 | 2026-05-21 | — | — | WO | disclosed |
| US-20260132112-A1 | COMPOUNDS | CTXT PTY LTD (AU) | 2026-05-14 | — | — | US | disclosed |
| US-20260124205-A1 | MODULATORS OF BETA CATENIN AND USES THEREOF | DEWPOINT THERAPEUTICS INC (US) | 2026-05-07 | — | — | US | disclosed |
| US-20260115296-A1 | COMPOUNDS AND METHODS FOR THE TARGETED DEGRADATION OF RAPIDLY ACCELERATED FIBROSARCOMA POLYPEPTIDES | UNIV YALE (US) | 2026-04-30 | — | — | US | disclosed |
| WO-2026090104-A1 | MODULATORS OF BETA CATENIN AND USES THEREOF | DEWPOINT THERAPEUTICS, INC. (US) | 2026-04-30 | — | — | WO | disclosed |
| EP-4731262-A1 | PHARMACEUTICAL COMPOSITION COMPRISING A QUINAZOLINE COMPOUND | Astellas Pharma Inc. (JP) | 2026-04-29 | — | — | EP | disclosed |
| US-20260109716-A1 | CEREBLON-BASED KRAS DEGRADING PROTACS AND USES RELATED THERETO | ARVINAS OPERATIONS, INC. (US) | 2026-04-23 | — | — | US | disclosed |
| EP-4293024-B1 | QUINAZOLINE COMPOUND FOR INDUCING DEGRADATION OF G12D MUTANT KRAS PROTEIN | ASTELLAS PHARMA INC (JP) | 2026-04-08 | — | — | EP | disclosed |
| WO-1990015599-A1 | MEDICAMENTS USEFUL IN CANCER THERAPY AND HAVING ANTIHISTAMINIC PROPERTIES | THE WELLCOME FOUNDATION LIMITED (GB) | 1990-12-27 | — | — | WO | disclosed |
| US-4923892-A | DOXEPIN DERIVATIVES; ANTIALLERGENS, ANTIASTHMATICS, ANTIHISTAMINES | BURROUGHS WELLCOME CO. (US) | 1990-05-08 | — | — | US | disclosed |
| EP-0214779-B1 | TRICYCLIC COMPOUNDS | THE WELLCOME FOUNDATION LIMITED (GB) | 1990-04-11 | — | — | EP | disclosed |
| EP-0351887-A1 | Tricyclic aromatic compounds | THE WELLCOME FOUNDATION LIMITED (GB) | 1990-01-24 | — | — | EP | disclosed |
| US-4871865-A | ANTIHISTAMINES | BURROUGHS WELLCOME CO. (US) | 1989-10-03 | — | — | US | disclosed |
| EP-0316022-A2 | Tricyclic compounds | THE WELLCOME FOUNDATION LIMITED (GB) | 1989-05-17 | — | — | EP | disclosed |
| EP-0214779-A1 | Tricyclic compounds | THE WELLCOME FOUNDATION LIMITED (GB) | 1987-03-18 | — | — | EP | disclosed |
| US-4289781-A | Anti-psychotic phthalimidine derivatives | ASTRA LAKEMEDEL AKTIEBOLAG (SE) | 1981-09-15 | — | — | US | disclosed |
| EP-0026749-A1 | Phthalimidine derivatives and pharmaceutical compositions containing them | Astra Läkemedel Aktiebolag (SE) | 1981-04-08 | — | — | EP | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (4 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20260124205-A1 | MODULATORS OF BETA CATENIN AND USES THEREOF | CTNNB1, CTNNA1, CTNND1 | NR4A2 242/4885L3MBTL1 812/4885ALDH1A1 1195/4885 |
| US-20260132112-A1 | COMPOUNDS | STING1, IRF3, CGAS | NR4A2 736/4885L3MBTL1 941/4885ALDH1A1 4143/4885 |
| US-20260109716-A1 | CEREBLON-BASED KRAS DEGRADING PROTACS AND USES RELATED THERETO | KRAS, CRBN, HRAS | NR4A2 1454/4885L3MBTL1 2165/4885ALDH1A1 3268/4885 |
| US-20260115296-A1 | COMPOUNDS AND METHODS FOR THE TARGETED DEGRADATION OF RAPIDLY ACCELERATED FIBROSARCOMA POLYPEPTIDES | CRBN, VHL, ADRM1 | NR4A2 2721/4885L3MBTL1 300/4885ALDH1A1 2777/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.